Novus Therapeutics, Inc. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 3,449,112 shares of its common stock, at a purchase price per share of $3.095, in a registered direct offering priced at-the-market.
April 30, 2019
· 7 min read